Skip to main content
Midas Edge

PLIANT THERAPEUTICS, INC.

For the period ended Mar 31, 2026. Filed May 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

PLRX$0.79-1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity (Unaudited)

Condensed Statements of Stockholders’ Equity

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Loss · AccumulatedDeficit · TotalStockholders’Equity
Common Stock
Shares · Amount
Balance at December 31, 202561,449,290$6$1,040,610$(15)$(859,396)$181,205
Issuance of common stock under benefit plans465,279—7474
Stock-based compensation4,2544,254
Net unrealized loss on short-term investments(326)(326)
Net loss(20,040)(20,040)
Balance at March 31, 202661,914,569$6$1,044,937$(341)$(879,436)$165,166

Condensed Statements of Stockholders’ Equity

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Gain/(Loss) · AccumulatedDeficit · TotalStockholders’Equity
Common Stock
Shares · Amount
Balance at December 31, 202460,860,838$6$1,013,806$321$(710,052)$304,081
Issuance of common stock under benefit plans525,345—498——498
Stock-based compensation——8,913——8,913
Net unrealized loss on short-term investments———(162)—(162)
Net loss————(56,166)(56,166)
Balance at March 31, 202561,386,183$6$1,023,217$159$(766,218)$257,164
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.